Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT (NCT07326839) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT
China120 participantsStarted 2025-12-10
Plain-language summary
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels \<360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Meeting the 2015 ACR/EULAR classification criteria for gout.
✓. Age 18-70 years.
✓. BMI ≥28 kg/m².
✓. Serum uric acid ≥480 μmol/L.
✓. Willing and able to comply with the study protocol.
Exclusion criteria
✕. Contraindications to orlistat or other gout medications.
✕. Severe hepatic or renal dysfunction.
✕. History of severe allergy or adverse reactions to study drugs.
✕. Pregnant or lactating women.
✕. Malignancy.
✕. Secondary gout.
✕. Poor compliance or inability to cooperate.
What they're measuring
1
The rate of patients achieving target serum uric acid levels